Home - News ( United States | United Kingdom | Italy | Germany ) - Football scores

Showing content from https://pubmed.ncbi.nlm.nih.gov/32702310/ below:

The impact of the COVID-19 pandemic on cancer deaths due to delays in diagnosis in England, UK: a national, population-based, modelling study

Affiliations

• ¹ Department of Non-communicable Disease Epidemiology, London School of Hygiene & Tropical Medicine, London, UK.
• ² School of Cancer and Pharmaceutical Sciences, King's College London, London, UK; Department of Oncology, Guy's and St Thomas' NHS Foundation Trust, London, UK.
• ³ Department of Health Services Research and Policy, London School of Hygiene & Tropical Medicine, London, UK.
• ⁴ School of Cancer and Pharmaceutical Sciences, King's College London, London, UK; Institute of Cancer Policy, King's College London, London, UK; Department of Oncology, Guy's and St Thomas' NHS Foundation Trust, London, UK.
• ⁵ Department of Health Services Research and Policy, London School of Hygiene & Tropical Medicine, London, UK; Institute of Cancer Policy, King's College London, London, UK; Department of Oncology, Guy's and St Thomas' NHS Foundation Trust, London, UK. Electronic address: ajay.aggarwal@lshtm.ac.uk.

• PMID: 32702310
• PMCID: PMC7417808
• DOI: 10.1016/S1470-2045(20)30388-0

Item in Clipboard

Camille Maringe et al. Lancet Oncol. 2020 Aug.

• ¹ Department of Non-communicable Disease Epidemiology, London School of Hygiene & Tropical Medicine, London, UK.
• ² School of Cancer and Pharmaceutical Sciences, King's College London, London, UK; Department of Oncology, Guy's and St Thomas' NHS Foundation Trust, London, UK.
• ³ Department of Health Services Research and Policy, London School of Hygiene & Tropical Medicine, London, UK.
• ⁴ School of Cancer and Pharmaceutical Sciences, King's College London, London, UK; Institute of Cancer Policy, King's College London, London, UK; Department of Oncology, Guy's and St Thomas' NHS Foundation Trust, London, UK.
• ⁵ Department of Health Services Research and Policy, London School of Hygiene & Tropical Medicine, London, UK; Institute of Cancer Policy, King's College London, London, UK; Department of Oncology, Guy's and St Thomas' NHS Foundation Trust, London, UK. Electronic address: ajay.aggarwal@lshtm.ac.uk.

• PMID: 32702310
• PMCID: PMC7417808
• DOI: 10.1016/S1470-2045(20)30388-0

Item in Clipboard

• Correction to Lancet Oncol 2020; 21: 1023-34.

  [No authors listed] [No authors listed] Lancet Oncol. 2021 Jan;22(1):e5. doi: 10.1016/S1470-2045(20)30752-X. Lancet Oncol. 2021. PMID: 33387506 Free PMC article. No abstract available.

Background: Since a national lockdown was introduced across the UK in March, 2020, in response to the COVID-19 pandemic, cancer screening has been suspended, routine diagnostic work deferred, and only urgent symptomatic cases prioritised for diagnostic intervention. In this study, we estimated the impact of delays in diagnosis on cancer survival outcomes in four major tumour types.

Methods: In this national population-based modelling study, we used linked English National Health Service (NHS) cancer registration and hospital administrative datasets for patients aged 15-84 years, diagnosed with breast, colorectal, and oesophageal cancer between Jan 1, 2010, and Dec 31, 2010, with follow-up data until Dec 31, 2014, and diagnosed with lung cancer between Jan 1, 2012, and Dec 31, 2012, with follow-up data until Dec 31, 2015. We use a routes-to-diagnosis framework to estimate the impact of diagnostic delays over a 12-month period from the commencement of physical distancing measures, on March 16, 2020, up to 1, 3, and 5 years after diagnosis. To model the subsequent impact of diagnostic delays on survival, we reallocated patients who were on screening and routine referral pathways to urgent and emergency pathways that are associated with more advanced stage of disease at diagnosis. We considered three reallocation scenarios representing the best to worst case scenarios and reflect actual changes in the diagnostic pathway being seen in the NHS, as of March 16, 2020, and estimated the impact on net survival at 1, 3, and 5 years after diagnosis to calculate the additional deaths that can be attributed to cancer, and the total years of life lost (YLLs) compared with pre-pandemic data.

Findings: We collected data for 32 583 patients with breast cancer, 24 975 with colorectal cancer, 6744 with oesophageal cancer, and 29 305 with lung cancer. Across the three different scenarios, compared with pre-pandemic figures, we estimate a 7·9-9·6% increase in the number of deaths due to breast cancer up to year 5 after diagnosis, corresponding to between 281 (95% CI 266-295) and 344 (329-358) additional deaths. For colorectal cancer, we estimate 1445 (1392-1591) to 1563 (1534-1592) additional deaths, a 15·3-16·6% increase; for lung cancer, 1235 (1220-1254) to 1372 (1343-1401) additional deaths, a 4·8-5·3% increase; and for oesophageal cancer, 330 (324-335) to 342 (336-348) additional deaths, 5·8-6·0% increase up to 5 years after diagnosis. For these four tumour types, these data correspond with 3291-3621 additional deaths across the scenarios within 5 years. The total additional YLLs across these cancers is estimated to be 59 204-63 229 years.

Interpretation: Substantial increases in the number of avoidable cancer deaths in England are to be expected as a result of diagnostic delays due to the COVID-19 pandemic in the UK. Urgent policy interventions are necessary, particularly the need to manage the backlog within routine diagnostic services to mitigate the expected impact of the COVID-19 pandemic on patients with cancer.

Funding: UK Research and Innovation Economic and Social Research Council.

Copyright © 2020 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY-NC-ND 4.0 license. Published by Elsevier Ltd.. All rights reserved.

PubMed Disclaimer

Conceptual framework for reallocation of…

Conceptual framework for reallocation of pre-pandemic referral routes in three modelling scenarios (A,…

Conceptual framework for reallocation of pre-pandemic referral routes in three modelling scenarios (A, B, and C) For breast cancer, in addition to patients on routine pathways, only 25% of patients diagnosed through screening (ie, the proportion of patients with tumour stage III or IV, node-positive, or metastatic disease) were reallocated to 2-week wait or emergency presentation in the pandemic scenarios. GP=general practitioner.

Estimated additional number of cancer…

Estimated additional number of cancer deaths for each pandemic scenario A–C, for breast…

Estimated additional number of cancer deaths for each pandemic scenario A–C, for breast cancer (A), colorectal cancer (B), lung cancer (C), and oesophageal cancer (D)

• Cancer diagnostic delay in the COVID-19 era: what happens next?

  Hamilton W. Hamilton W. Lancet Oncol. 2020 Aug;21(8):1000-1002. doi: 10.1016/S1470-2045(20)30391-0. Epub 2020 Jul 20. Lancet Oncol. 2020. PMID: 32702312 Free PMC article. No abstract available.

• Effect of radiotherapy interruption due to COVID-19 outbreak.

  Yu D, Hu W, Chen L, Fu Z, Song Q, Li X. Yu D, et al. Radiother Oncol. 2021 Feb;155:1-2. doi: 10.1016/j.radonc.2020.09.055. Epub 2020 Oct 11. Radiother Oncol. 2021. PMID: 33053379 Free PMC article. No abstract available.

• Too long to wait: the impact of COVID-19 on elective surgery.

  The Lancet Rheumatology. The Lancet Rheumatology. Lancet Rheumatol. 2021 Feb;3(2):e83. doi: 10.1016/S2665-9913(21)00001-1. Epub 2021 Jan 28. Lancet Rheumatol. 2021. PMID: 33778775 Free PMC article. No abstract available.

• Economic impact of avoidable cancer deaths caused by diagnostic delay during the COVID-19 pandemic: A national population-based modelling study in England, UK.

  Gheorghe A, Maringe C, Spice J, Purushotham A, Chalkidou K, Rachet B, Sullivan R, Aggarwal A. Gheorghe A, et al. Eur J Cancer. 2021 Jul;152:233-242. doi: 10.1016/j.ejca.2021.04.019. Epub 2021 May 5. Eur J Cancer. 2021. PMID: 34049776 Free PMC article.

• Effect of delays in the 2-week-wait cancer referral pathway during the COVID-19 pandemic on cancer survival in the UK: a modelling study.

  Sud A, Torr B, Jones ME, Broggio J, Scott S, Loveday C, Garrett A, Gronthoud F, Nicol DL, Jhanji S, Boyce SA, Williams M, Riboli E, Muller DC, Kipps E, Larkin J, Navani N, Swanton C, Lyratzopoulos G, McFerran E, Lawler M, Houlston R, Turnbull C. Sud A, et al. Lancet Oncol. 2020 Aug;21(8):1035-1044. doi: 10.1016/S1470-2045(20)30392-2. Epub 2020 Jul 20. Lancet Oncol. 2020. PMID: 32702311 Free PMC article.

• Economic impact of avoidable cancer deaths caused by diagnostic delay during the COVID-19 pandemic: A national population-based modelling study in England, UK.

  Gheorghe A, Maringe C, Spice J, Purushotham A, Chalkidou K, Rachet B, Sullivan R, Aggarwal A. Gheorghe A, et al. Eur J Cancer. 2021 Jul;152:233-242. doi: 10.1016/j.ejca.2021.04.019. Epub 2021 May 5. Eur J Cancer. 2021. PMID: 34049776 Free PMC article.

• Impact of the COVID-19 pandemic on health-care use among patients with cancer in England, UK: a comprehensive phase-by-phase time-series analysis across attendance types for 38 cancers.

  Tan YY, Chang WH, Katsoulis M, Denaxas S, King KC, Cox MP, Davie C, Balloux F, Lai AG. Tan YY, et al. Lancet Digit Health. 2024 Oct;6(10):e691-e704. doi: 10.1016/S2589-7500(24)00152-3. Lancet Digit Health. 2024. PMID: 39332853

• COVID-19 and liver cancer: lost patients and larger tumours.

  Geh D, Watson R, Sen G, French JJ, Hammond J, Turner P, Hoare T, Anderson K, McNeil M, McPherson S, Masson S, Dyson J, Donnelly M, MacDougal L, Patel P, Hudson M, Anstee QM, White S, Robinson S, Pandanaboyana S, Walker L, McCain M, Bury Y, Raman S, Burt A, Parkinson D, Haugk B, Darne A, Wadd N, Asghar S, Mariappan L, Margetts J, Stenberg B, Scott J, Littler P, Manas DM, Reeves HL. Geh D, et al. BMJ Open Gastroenterol. 2022 Apr;9(1):e000794. doi: 10.1136/bmjgast-2021-000794. BMJ Open Gastroenterol. 2022. PMID: 35450934 Free PMC article. Review.

• Delays in cancer diagnosis: challenges and opportunities in Europe.

  Renzi C, Odelli S, Morani F, Benitez Majano S, Signorelli C. Renzi C, et al. Acta Biomed. 2023 Aug 30;94(S3):e2023161. doi: 10.23750/abm.v94iS3.14513. Acta Biomed. 2023. PMID: 37695178 Review.

• A new model to prioritize waiting lists for elective surgery under the COVID-19 pandemic pressure.

  Valente R, Di Domenico S, Mascherini M, Santori G, Papadia F, Orengo G, Gratarola A, Cafiero F, De Cian F; Collaborators. Valente R, et al. Br J Surg. 2021 Jan 27;108(1):e12-e14. doi: 10.1093/bjs/znaa028. Br J Surg. 2021. PMID: 33640936 Free PMC article. No abstract available.

• AGA Rapid Review and Guideline for SARS-CoV2 Testing and Endoscopy Post-Vaccination: 2021 Update.

  Sultan S, Siddique SM, Singh S, Altayar O, Caliendo AM, Davitkov P, Feuerstein JD, Kaul V, Lim JK, Mustafa RA, Falck-Ytter Y, Inadomi JM; American Gastroenterological Association. Sultan S, et al. Gastroenterology. 2021 Sep;161(3):1011-1029.e11. doi: 10.1053/j.gastro.2021.05.039. Epub 2021 May 21. Gastroenterology. 2021. PMID: 34029569 Free PMC article.

• Impact of the COVID-19 Pandemic on Gastric Cancer Screening in South Korea: Results From the Korean National Cancer Screening Survey (2017-2021).

  Lee K, Suh M, Jun JK, Choi KS. Lee K, et al. J Gastric Cancer. 2022 Oct;22(4):264-272. doi: 10.5230/jgc.2022.22.e36. J Gastric Cancer. 2022. PMID: 36316105 Free PMC article. Review.

• Cancer surgery in the era of COVID-19 pandemic: Changing dynamics.

  Garg PK, Kaul P, Choudhary D, Singh MP, Tiwari AR. Garg PK, et al. J Surg Oncol. 2020 Nov;122(6):1262-1263. doi: 10.1002/jso.26156. Epub 2020 Aug 5. J Surg Oncol. 2020. PMID: 32761619 Free PMC article. No abstract available.

• Impact of COVID-19 on colorectal cancer early diagnosis pathway: retrospective cohort study.

  Abdellatif M, Salama Y, Alhammali T, Eltweri AM. Abdellatif M, et al. Br J Surg. 2021 Apr 30;108(4):e146-e147. doi: 10.1093/bjs/znaa122. Br J Surg. 2021. PMID: 33792641 Free PMC article. No abstract available.

1. 1. UK Government Coronavirus (COVID-19) guidance. 2020. https://www.gov.uk/government/collections/coronavirus-covid-19-list-of-g...
2. 1. Neal RD, Tharmanathan P, France B. Is increased time to diagnosis and treatment in symptomatic cancer associated with poorer outcomes? Systematic review. Br J Cancer. 2015;112(suppl 1):S92–S107. - PMC - PubMed
3. 1. Tørring ML, Murchie P, Esteva M. The signal and the noise in colorectal cancer diagnosis: exploring and explaining the relationship between diagnostic delays and stage at diagnosis using the Ca-PRI Colorectal Cancer Collaboration dataset. Eur J Cancer Care. 2015;24(suppl 2):22.
4. 1. NHS England . NHS England and NHS Improvement; April 7, 2020. Publication approval reference 001559. Specialty guides for patient management during the coronavirus pandemic. Clinical guide for the management of essential cancer surgery for adults during the coronavirus pandemic.
5. 1. National Institute for Health and Care Excellence . National Institute for Health and Care Excellence; March 20, 2020. COVID-19 rapid guidelines: delivery of systemic anticancer treatments.https://www.nice.org.uk/guidance/ng161/resources/covid19-rapid-guideline... - PubMed

RetroSearch is an open source project built by @garambo | Open a GitHub Issue

Search and Browse the WWW like it's 1997 | Search results from DuckDuckGo

HTML: 3.2 | Encoding: UTF-8 | Version: 0.7.3